Powered by ZigaForm version 3.9.8.8

Public Alert No. 046/2022 – Alert on the Distribution and Sale of Falsified Daonil 5mg Tablets

December 14, 2022,

The National Agency for Food and Drug Administration and Control (NAFDAC) is notifying Healthcare providers and the public on the distribution and sale of falsified Daonil 5mg tablets discovered in Idumota, Lagos state and reported by Sanofi. The product as reported by Sanofi is referred to as DAO-NI 0016.

Laboratory analysis of the product DAO-NI 0016 was conducted at the company’s anti-counterfeit laboratory in Tours, France confirmed that the product is falsified.

Product details of the counterfeit DAO-NI 0016 is as follows:

Product Name: Daonil 5mg

Batch No.: OPA6D

Expiry date: August 2023 (08/2023)

The authentic product (DAO-NI 0016) has batch number OPA6D with expiration date August 2022. The expiration date on the box and blisters of the counterfeit product is August 2023. Report of analysis observed the reuse and/or relabelling of packaging from authentic expired product by changing the expiration date from 08/2022 to 08/2023.

Daonil 5 mg tablet is an anti-diabetic medicine containing glibenclamide as its active ingredient. It is used to treat type 2 diabetes mellitus.

The sale and use of the counterfeit Daonil 5mg tablets poses a risk to patients health and safety.

NAFDAC advice wholesalers, distributors, pharmacies and consumers to ensure that products are obtained from authentic and reliable sources. Increased vigilance is hereby encouraged within the supply chain to avoid infiltration of the counterfeit Daonil 5mg tablets and to prevent the administration of the product to unsuspecting patient by healthcare providers. The products’ authenticity and physical condition should be carefully checked. 

Anybody in possession of the counterfeit product should immediately discontinue sale or use and submit stock to the nearest NAFDAC office.

Healthcare providers and consumers are encouraged to report any suspicion of counterfeit drug product to NAFDAC on 0800-162-3322 or email: sf.alert@nafdac.gov.ng, report adverse events experienced with the use of the counterfeit product to the nearest NAFDAC office, via pharmacovigilance@nafdac.gov.ng, E-reporting platforms available at www.nafdac.gov.ng or via the Med- safety application for download on android and IOS stores.

NAFDAC……..Customer-focused, Agency-minded!!!

Signed Management

Was this post helpful?